Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.46 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.38 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9795914 | 0.98 | PPARG (0.48) | PPARGCSNK1EESR1PDE5APPARA | |
| SCHEMBL3936218 | 0.98 | PPARG (0.48) | PPARGCSNK1EESR1PDE5APPARA | |
| SCHEMBL477348 | 0.94 | ESR1 (0.42) | PPARGCSNK1EESR1PDE5AALDH1A1 | |
| SCHEMBL539922 | 0.88 | ESR1 (0.43) | PPARGESR1GAALMNA | |
| SCHEMBL7328907 | 0.83 | ESR1 (0.39) | PPARGESR1ALDH1A1GAAKDM4E | |
| SCHEMBL8216569 | 0.81 | ALDH1A1 (0.46) | PPARGCSNK1EPPARAALDH1A1CNR2 | |
| SCHEMBL20543855 | 0.81 | SOAT1 (0.42) | PPARGCSNK1EALDH1A1 | |
| SCHEMBL7648740 | 0.81 | CYSLTR2 (0.48) | PPARGCSNK1EESR1ALDH1A1TP53 | |
| SCHEMBL6547454 | 0.81 | CYSLTR2 (0.48) | PPARGCSNK1EESR1ALDH1A1TP53 | |
| SCHEMBL6690451 | 0.81 | TSHR (0.52) | PPARGCSNK1EPPARAALDH1A1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572927-B2 | Method of producing an o-disubstituted aromatic compound, and method of producing a monosubstituted-monohaloaromatic compound | FUJIFILM CORPORATION (JP) | 2009-08-11 | — | — | US | disclosed |
| US-20080194816-A1 | Method of producing an o-disubstituted aromatic compound, and method of producing a monosubstituted-monohaloaromatic compound | FUJIFILM CORPORATION (JP) | 2008-08-14 | — | — | US | disclosed |
| US-5006534-A | Substituted ethers, thioethers and amines for use as lipoxygenase inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 1991-04-09 | — | — | US | disclosed |
| EP-0224086-B1 | SUBSTITUTED BENZYL ETHERS | BAYER AG (DE) | 1990-10-24 | — | — | EP | disclosed |
| EP-0224086-A2 | Substituted benzyl ethers | BAYER AG (DE) | 1987-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194816-A1 | Method of producing an o-disubstituted aromatic compound, and method of producing a monosubstituted-monohaloaromatic compound | DDT, OXER1, OSTC | PPARG 2475/4885CSNK1E 4860/4885ESR1 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.